《人民日报》、《中国医药报》、《科技日报》,对贵州瑞和制药有限公司出资860万元买得一项具有填补国内空白的高科技成果——主治前列腺增生、前列腺炎的纯中药制剂“川参通注射液”给予肯定报导。该药1999年被国家药品监督管理局定为国家级二类新药,它以全新用药理念、将药物注入前列腺体内,从根本上解 “People’s Daily”, “China Medical News” and “Science and Technology Daily” have invested RMB 8.6 million in Guizhou Ruihe Pharmaceutical Co., Ltd. to buy a high-tech product that fills a gap in the country - pure Chinese medicine that treats benign prostatic hyperplasia and prostatitis. Preparation “Chuan Shen Tong injection ” give positive reports. This medicine was designated as a national second class new drug by the State Drug Administration in 1999. It uses a brand-new drug concept to inject drugs into the body of the prostate and fundamentally solve it.